| Health / Medical Topics |
NY-ESO-1/GLA-SE Vaccine ID-G305
A cancer vaccine composed of a recombinant form of the tumor antigen NY-ESO-1 and glucopyranosyl lipid adjuvant (GLA)-stable emulsion (GLA-SE), with potential antineoplastic and immunomodulating activities. Upon intramuscular injection, the adjuvant portion of the NY-ESO-1/GLA-SE vaccine ID-G30 binds to toll-like receptor subtype 4 (TLR-4) expressed on dendritic cells (DCs), monocytes, macrophages and B cells. The activated DCs present the NY-ESO-1 antigen to Th1 CD4 T-lymphocytes. This leads to the induction of cytotoxic T lymphocytes (CTLs) and the killing of NY-ESO-1-expressing tumor cells. This vaccine also induces specific antibody responses and increases the production of inflammatory cytokines. (NCI Thesaurus)
YOU MAY ALSO LIKE
Human autologous peripheral blood lymphocytes (PBLs) transduced with a retroviral vector encoding a T cell receptor (TCR) specific for the cancer-testis antigen…
A cancer vaccine consisting of an immunogenic peptide derived from the cancer-testis antigen (NY-ESO-1) and emulsified in the immunoadjuvant Montanide ISA-51 VG,…
A plasmid DNA encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1 with potential immunostimulating and antitumor activities. Upon administration, NY-ESO-1…
A cancer vaccine consisting of an immunogenic peptide derived from the cancer-testis antigen (NY-ESO-1), an antigen found in normal testis and various…
A regional lymph node TNM finding indicating that the status of regional lymph nodes cannot be assessed.
A regimen consisting of vincristine, doxorubicin, etoposide alternating with cyclophosphamide and etoposide, administered with radiation therapy and used for the treatment of…
